A recent study wherein HLA-A*02 antigen-specific antibody (A2-CAR) human CD8+ Tregs reduced mismatched HLA-A*02 skin graft rejection and prevented xenogeneic GvHD in NSG mice [87] presents a novel platform for CD8+Treg therapy. The gene discussed is CD8A; the disease is graft versus host disease.